Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News Sarepta files controversial Duchenne drug in EU US biotech seeks conditional approval for eteplirsen in EU.
News PTC's muscular dystrophy drug can stay on EU market - regula... But PTC must conduct further trial to confirm Translarna's benefits.
News Europe delays review of PTC's Duchenne drug Review of marketing authorisation delayed, new trial likely.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
